Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.
No abstract available.
Patients with lower-risk
Accumulating evidence implicates innate immune activation in the pathobiology of
Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.
The only curative treatment in patients with intermediate or high-risk myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell transplantation (HSCT), which usually results in a long-term, disease-free survival rate of between 30% and 50%, depending on the disease risk and the type of donor. In patients without an HLA-matched sibling donor, a family haploidentical donor is an alternative option.